Vera Therapeutics (NASDAQ:VERA) Releases Quarterly Earnings Results, Beats Expectations By $0.32 EPS

Key Points

• Vera Therapeutics reported a quarterly loss of $1.30 per share, beating analyst estimates of a $1.62 loss; revenue of $10.28 million also topped the $3.42 million consensus.
• Its therapy showed promising kidney-function results in a 104-week trial, and the company has sought full FDA approval. Since the July U.S. approval, the early launch generated about 700 Patient Start Forms and $10.3 million in quarterly product revenue.
• Commercialization contributed to increased costs: Vera posted a $93.7 million quarterly net loss and used $305.9 million in operating cash during the first nine months of 2026. It ended the quarter with $384 million in cash and marketable securities and borrowed $75 million in October.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.30) earnings per share for the quarter, beating analysts' consensus estimates of ($1.62) by $0.32, FiscalAI reports. The company had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million.

Here are the key takeaways from Vera Therapeutics' conference call:

• TRUTAKNA showed strong kidney-function results in ORIGIN 3: At 104 weeks, it reduced the risk of kidney disease progression by 76% versus placebo, with kidney-function decline near a physiologic rate. Vera submitted an FDA application seeking full approval and plans an EU application in the first quarter of 2027.
• The early U.S. launch generated about 700 Patient Start Forms since the July approval, and third-quarter product revenue was $10.3 million; management said roughly half the revenue reflected demand and half inventory. The company said prescriptions span patients with both higher and lower proteinuria, while acknowledging that adoption is still at an early stage.
• Interim PIONEER results showed a 52% reduction in proteinuria from baseline at week 24 among 101 adults across broader IgA nephropathy cohorts, including patients with lower kidney function. Results in primary membranous nephropathy were preliminary, based on 16 patients.
• Spending and cash use increased as Vera funded commercialization: third-quarter net loss was $93.7 million, and operating cash use totaled $305.9 million for the first nine months of 2026. The company reported $384 million in cash and marketable securities at quarter-end and borrowed $75 million in October; additional debt capacity is subject to conditions.

Vera Therapeutics Trading Down 5.7%

Shares of VERA stock traded down $1.83 on Thursday, reaching $30.14. The company had a trading volume of 1,419,234 shares, compared to its average volume of 1,622,788. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.17 billion, a PE ratio of -5.14 and a beta of 1.07. The company has a 50-day moving average of $31.83 and a 200-day moving average of $36.84. Vera Therapeutics has a 12 month low of $23.05 and a 12 month high of $56.05.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on VERA shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Leerink Partners assumed coverage on shares of Vera Therapeutics in a report on Monday, October 12th. They issued a "market perform" rating and a $34.00 price objective on the stock. Wedbush restated a "neutral" rating and issued a $34.00 price objective on shares of Vera Therapeutics in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $76.86.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 18,500 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company's research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera's lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.